ImmunityBio, Inc. (IBRX) scores 43 out of 100 on boothcheck's 11-model valuation framework. Verdict: Avoid The estimated fair value is 0.08, representing a 99% premium to fair value. Quantitative score: 38/100. Qualitative score: 90/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.